ArticleInternational journal of molecular sciences2021

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.

Katja Seipel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.